Cargando…
The clinical application of PIVKA‐II in hepatocellular carcinoma and chronic liver diseases: A multi‐center study in China
BACKGROUND: Due to the absence of specific symptoms and low survival rate, efficient biomarkers for hepatocellular carcinoma (HCC) diagnosis are urgently required. The purpose of this study was to evaluate the diagnostic performance of protein induced by vitamin K absence or antagonist‐II (PIVKA‐II)...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605129/ https://www.ncbi.nlm.nih.gov/pubmed/34590755 http://dx.doi.org/10.1002/jcla.24013 |
_version_ | 1784602109083123712 |
---|---|
author | Ji, Jun Liu, Lijuan Jiang, Feifei Wen, Xue Zhang, Yu Li, Shengcong Lou, Jinli Wang, Ying Liu, Ning Guo, Qiuyan Jia, Yongmei Gao, Chunfang |
author_facet | Ji, Jun Liu, Lijuan Jiang, Feifei Wen, Xue Zhang, Yu Li, Shengcong Lou, Jinli Wang, Ying Liu, Ning Guo, Qiuyan Jia, Yongmei Gao, Chunfang |
author_sort | Ji, Jun |
collection | PubMed |
description | BACKGROUND: Due to the absence of specific symptoms and low survival rate, efficient biomarkers for hepatocellular carcinoma (HCC) diagnosis are urgently required. The purpose of this study was to evaluate the diagnostic performance of protein induced by vitamin K absence or antagonist‐II (PIVKA‐II) and to determine the optimal cutoff values for HBV infection‐related HCC. METHODS: We conducted a cross‐sectional, multi‐center study in China to ascertain the cutoff value for HCC patients in the context of CHB‐ and HBV‐related cirrhosis. The receiver operating characteristic curve (ROC) and the area under the curve (AUC) were used to evaluate the diagnostic performance of PIVKA‐II. RESULTS: This study enrolled 784 subjects and demonstrated that PIVKA‐II had a sensitivity of 84.08% and a specificity of 90.43% in diagnosis HCC from chronic liver diseases. PIVKA‐II at a cutoff of 37.5 mAU/mL yielded an AUC of 0.9737 (sensitivity 91.78% and specificity 96.30%) in discriminating HCC from chronic hepatitis B (CHB) patients. PIVKA‐II at a cutoff of 45 mAU/mL yielded an AUC of 0.9419 (sensitivity 77.46% and specificity 95.12%) in discriminating HCC‐ from HBV‐related cirrhosis patients. Furthermore, using a cutoff value of 40 mAU/mL for PIVKA‐II as an HCC marker, only 4.81% (15/312) was positive in chronic hepatitis and 12.80% (37/289) in cirrhosis patients, revealing the satisfactory specificity of PIVKA‐II in chronic liver disease of different etiologies. CONCLUSION: Our data indicated that PIVKA‐II had satisfactory diagnostic efficiencies and could be used as a screening or surveillance biomarker in HCC high‐risk population. |
format | Online Article Text |
id | pubmed-8605129 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86051292021-11-24 The clinical application of PIVKA‐II in hepatocellular carcinoma and chronic liver diseases: A multi‐center study in China Ji, Jun Liu, Lijuan Jiang, Feifei Wen, Xue Zhang, Yu Li, Shengcong Lou, Jinli Wang, Ying Liu, Ning Guo, Qiuyan Jia, Yongmei Gao, Chunfang J Clin Lab Anal Research Articles BACKGROUND: Due to the absence of specific symptoms and low survival rate, efficient biomarkers for hepatocellular carcinoma (HCC) diagnosis are urgently required. The purpose of this study was to evaluate the diagnostic performance of protein induced by vitamin K absence or antagonist‐II (PIVKA‐II) and to determine the optimal cutoff values for HBV infection‐related HCC. METHODS: We conducted a cross‐sectional, multi‐center study in China to ascertain the cutoff value for HCC patients in the context of CHB‐ and HBV‐related cirrhosis. The receiver operating characteristic curve (ROC) and the area under the curve (AUC) were used to evaluate the diagnostic performance of PIVKA‐II. RESULTS: This study enrolled 784 subjects and demonstrated that PIVKA‐II had a sensitivity of 84.08% and a specificity of 90.43% in diagnosis HCC from chronic liver diseases. PIVKA‐II at a cutoff of 37.5 mAU/mL yielded an AUC of 0.9737 (sensitivity 91.78% and specificity 96.30%) in discriminating HCC from chronic hepatitis B (CHB) patients. PIVKA‐II at a cutoff of 45 mAU/mL yielded an AUC of 0.9419 (sensitivity 77.46% and specificity 95.12%) in discriminating HCC‐ from HBV‐related cirrhosis patients. Furthermore, using a cutoff value of 40 mAU/mL for PIVKA‐II as an HCC marker, only 4.81% (15/312) was positive in chronic hepatitis and 12.80% (37/289) in cirrhosis patients, revealing the satisfactory specificity of PIVKA‐II in chronic liver disease of different etiologies. CONCLUSION: Our data indicated that PIVKA‐II had satisfactory diagnostic efficiencies and could be used as a screening or surveillance biomarker in HCC high‐risk population. John Wiley and Sons Inc. 2021-09-30 /pmc/articles/PMC8605129/ /pubmed/34590755 http://dx.doi.org/10.1002/jcla.24013 Text en © 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Ji, Jun Liu, Lijuan Jiang, Feifei Wen, Xue Zhang, Yu Li, Shengcong Lou, Jinli Wang, Ying Liu, Ning Guo, Qiuyan Jia, Yongmei Gao, Chunfang The clinical application of PIVKA‐II in hepatocellular carcinoma and chronic liver diseases: A multi‐center study in China |
title | The clinical application of PIVKA‐II in hepatocellular carcinoma and chronic liver diseases: A multi‐center study in China |
title_full | The clinical application of PIVKA‐II in hepatocellular carcinoma and chronic liver diseases: A multi‐center study in China |
title_fullStr | The clinical application of PIVKA‐II in hepatocellular carcinoma and chronic liver diseases: A multi‐center study in China |
title_full_unstemmed | The clinical application of PIVKA‐II in hepatocellular carcinoma and chronic liver diseases: A multi‐center study in China |
title_short | The clinical application of PIVKA‐II in hepatocellular carcinoma and chronic liver diseases: A multi‐center study in China |
title_sort | clinical application of pivka‐ii in hepatocellular carcinoma and chronic liver diseases: a multi‐center study in china |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605129/ https://www.ncbi.nlm.nih.gov/pubmed/34590755 http://dx.doi.org/10.1002/jcla.24013 |
work_keys_str_mv | AT jijun theclinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT liulijuan theclinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT jiangfeifei theclinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT wenxue theclinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT zhangyu theclinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT lishengcong theclinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT loujinli theclinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT wangying theclinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT liuning theclinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT guoqiuyan theclinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT jiayongmei theclinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT gaochunfang theclinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT jijun clinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT liulijuan clinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT jiangfeifei clinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT wenxue clinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT zhangyu clinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT lishengcong clinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT loujinli clinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT wangying clinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT liuning clinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT guoqiuyan clinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT jiayongmei clinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina AT gaochunfang clinicalapplicationofpivkaiiinhepatocellularcarcinomaandchronicliverdiseasesamulticenterstudyinchina |